Last reviewed · How we verify

Chloasma — Treatment Landscape & Competitive Intelligence

Chloasma (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Chloasma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Tri-Luma HYDROQUINONE Galderma Labs Lp Melanin Synthesis Inhibitor [EPC] Carbonic anhydrase 2 2002-01-01
Retin-A TRETINOIN Bausch Health Retinoid [EPC] Nuclear receptor ROR-beta 1971-01-01
Derma-Smoothe/Fs FLUOCINOLONE ACETONIDE Eurofarma Corticosteroid [EPC] Glucocorticoid receptor 1963-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 2 drugs in Chloasma
  2. Bausch Health · 1 drug in Chloasma
  3. Eurofarma · 1 drug in Chloasma
  4. Galderma Labs Lp · 1 drug in Chloasma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Chloasma:

Cite this brief

Drug Landscape (2026). Chloasma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chloasma. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing